AU2005101039B4 - Stable Parasiticide Composition - Google Patents
Stable Parasiticide Composition Download PDFInfo
- Publication number
- AU2005101039B4 AU2005101039B4 AU2005101039A AU2005101039A AU2005101039B4 AU 2005101039 B4 AU2005101039 B4 AU 2005101039B4 AU 2005101039 A AU2005101039 A AU 2005101039A AU 2005101039 A AU2005101039 A AU 2005101039A AU 2005101039 B4 AU2005101039 B4 AU 2005101039B4
- Authority
- AU
- Australia
- Prior art keywords
- acid
- amount
- composition
- tetramisole
- macrocyclic lactone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims description 38
- 230000000590 parasiticidal effect Effects 0.000 title description 7
- 239000002297 parasiticide Substances 0.000 title description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 150000002596 lactones Chemical class 0.000 claims description 19
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 16
- 229960001614 levamisole Drugs 0.000 claims description 16
- 150000007524 organic acids Chemical class 0.000 claims description 12
- 229920005862 polyol Polymers 0.000 claims description 11
- 150000003077 polyols Chemical class 0.000 claims description 10
- 229940093915 gynecological organic acid Drugs 0.000 claims description 9
- 235000005985 organic acids Nutrition 0.000 claims description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 235000011054 acetic acid Nutrition 0.000 claims description 7
- 229960000583 acetic acid Drugs 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- -1 C 6 carboxylic acid Chemical class 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229960000250 adipic acid Drugs 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 239000005660 Abamectin Substances 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 6
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 5
- 150000001556 benzimidazoles Chemical class 0.000 description 5
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- JMPFSEBWVLAJKM-UHFFFAOYSA-N N-{5-chloro-4-[(4-chlorophenyl)(cyano)methyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide Chemical compound ClC=1C=C(NC(=O)C=2C(=C(I)C=C(I)C=2)O)C(C)=CC=1C(C#N)C1=CC=C(Cl)C=C1 JMPFSEBWVLAJKM-UHFFFAOYSA-N 0.000 description 4
- 229950008167 abamectin Drugs 0.000 description 4
- 229960002669 albendazole Drugs 0.000 description 4
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 229950004178 closantel Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- CCSONKKTCMHYFI-UHFFFAOYSA-N pyrido[3,4-f]quinoxaline Chemical class C1=NC=C2C3=NC=CN=C3C=CC2=C1 CCSONKKTCMHYFI-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 3
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960002418 ivermectin Drugs 0.000 description 3
- 229960003439 mebendazole Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229950003126 oxyclozanide Drugs 0.000 description 2
- JYWIYHUXVMAGLG-UHFFFAOYSA-N oxyclozanide Chemical compound OC1=C(Cl)C=C(Cl)C=C1NC(=O)C1=C(O)C(Cl)=CC(Cl)=C1Cl JYWIYHUXVMAGLG-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960002957 praziquantel Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- WCBVUETZRWGIJQ-UHFFFAOYSA-N 2-[[(methoxycarbonylamino)-(2-nitro-5-propylsulfanylanilino)methylidene]amino]ethanesulfonic acid Chemical compound CCCSC1=CC=C([N+]([O-])=O)C(NC(NC(=O)OC)=NCCS(O)(=O)=O)=C1 WCBVUETZRWGIJQ-UHFFFAOYSA-N 0.000 description 1
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- HMCCXLBXIJMERM-UHFFFAOYSA-N Febantel Chemical compound C1=C(NC(NC(=O)OC)=NC(=O)OC)C(NC(=O)COC)=CC(SC=2C=CC=CC=2)=C1 HMCCXLBXIJMERM-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- YRWLZFXJFBZBEY-UHFFFAOYSA-N N-(6-butyl-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCCC1=CC=C2N=C(NC(=O)OC)NC2=C1 YRWLZFXJFBZBEY-UHFFFAOYSA-N 0.000 description 1
- RAOCRURYZCVHMG-UHFFFAOYSA-N N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229920003082 Povidone K 90 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- ICKMASVVMCGZLR-UHFFFAOYSA-N [2-[(4-chlorophenyl)carbamoyl]-4,6-diiodophenyl] acetate Chemical compound CC(=O)OC1=C(I)C=C(I)C=C1C(=O)NC1=CC=C(Cl)C=C1 ICKMASVVMCGZLR-UHFFFAOYSA-N 0.000 description 1
- NRFGEDASJHBPPN-UHFFFAOYSA-N [2-bromo-6-[(4-bromophenyl)carbamothioyl]-4-chlorophenyl] acetate Chemical compound CC(=O)OC1=C(Br)C=C(Cl)C=C1C(=S)NC1=CC=C(Br)C=C1 NRFGEDASJHBPPN-UHFFFAOYSA-N 0.000 description 1
- OSWRVYBYIGOAEZ-UHFFFAOYSA-N acetic acid;2-hydroxypropanoic acid Chemical compound CC(O)=O.CC(O)C(O)=O OSWRVYBYIGOAEZ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- VXTGHWHFYNYFFV-UHFFFAOYSA-N albendazole S-oxide Chemical compound CCCS(=O)C1=CC=C2NC(NC(=O)OC)=NC2=C1 VXTGHWHFYNYFFV-UHFFFAOYSA-N 0.000 description 1
- 229950010075 albendazole sulfoxide Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229950005372 brotianide Drugs 0.000 description 1
- 229960003475 cambendazole Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229950010946 clioxanide Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- BSBSDQUZDZXGFN-UHFFFAOYSA-N cythioate Chemical compound COP(=S)(OC)OC1=CC=C(S(N)(=O)=O)C=C1 BSBSDQUZDZXGFN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 1
- 229960003997 doramectin Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960005282 febantel Drugs 0.000 description 1
- 229960005473 fenbendazole Drugs 0.000 description 1
- HDDSHPAODJUKPD-UHFFFAOYSA-N fenbendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 HDDSHPAODJUKPD-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 description 1
- 229940099245 milbemycin oxime Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 1
- 229960004816 moxidectin Drugs 0.000 description 1
- QNSIFYWAPWSAIJ-UHFFFAOYSA-N naftalofos Chemical compound C1=CC(C(N(OP(=O)(OCC)OCC)C2=O)=O)=C3C2=CC=CC3=C1 QNSIFYWAPWSAIJ-UHFFFAOYSA-N 0.000 description 1
- 229950006716 netobimin Drugs 0.000 description 1
- 229960001920 niclosamide Drugs 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 229960004454 oxfendazole Drugs 0.000 description 1
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 description 1
- 229960002762 oxibendazole Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229950007337 parbendazole Drugs 0.000 description 1
- 239000004540 pour-on Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QZWHWHNCPFEXLL-UHFFFAOYSA-N propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CC=C2N=C1C1=CSC=N1 QZWHWHNCPFEXLL-UHFFFAOYSA-N 0.000 description 1
- 229950002980 rafoxanide Drugs 0.000 description 1
- NEMNPWINWMHUMR-UHFFFAOYSA-N rafoxanide Chemical compound OC1=C(I)C=C(I)C=C1C(=O)NC(C=C1Cl)=CC=C1OC1=CC=C(Cl)C=C1 NEMNPWINWMHUMR-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- YFNCATAIYKQPOO-UHFFFAOYSA-N thiophanate Chemical compound CCOC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OCC YFNCATAIYKQPOO-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000323 triclabendazole Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
AUSTRALIA
Patents Act 1990 Jurox Pty Ltd COMPLETE SPECIFICATION INNOVATION PATENT Invention Title: Stable Parasiticide Composition The following statement is a full description of this invention including the best method of performing it known to us:- Technical Field U This invention relates to parasiticide compositions for use in the treatment of parasitic infestations of animals and in particular to compositions including tetramisoles and ,1 macrocyclic lactones.
Background art Insecticide and parasiticide compositions are commonly used in the veterinary field to deliver active substances for controlling pests in and on animals. There are a number of parasiticide actives that are known to be used in this type of treatment. The CN commonly used actives are from the chemical classes of benzimidazoles, salicylanilides, macrocyclic lactones, tetramisoles, pyrazino isoquinoline derivative and organophosphates. A combination of actives is often employed as a combination can be more effective than treatment with a single active in the face of resistant parasites and the use of combinations may help to delay the development of resistance.
It has been difficult to formulate liquid formulations which contain a mixture of some classes of actives due to chemical incompatibility between active compounds, hydrolysis, low solubility of the active compounds and instability at alkali pH.
When formulating a preparation containing tetramisoles and macrocyclic lactones, traditional formulations require micelles or emulsions to stabilise the macrocyclic lactones at alkaline pH or the use of a salt of tetramisole in an acidic medium. Emulsions and micelle solutions contain large amounts of surfactants and tend to create foaming problems during manufacturing and use in the field. Emulsions and micelle solutions tend to foam when agitated during transport or shaking. Foaming traps air bubbles in the product and therefore a 30 ml dose may be altered to contain for example, 25 mL liquid and 5 mL air. This may cause non-uniformity in dose volume.
Emulsions may also suffer from emulsion breakdown at high or low storage temperature, which causes break down of the formulation.
Disclosure of invention Tetramisoles have a high alkali pH It is desirable therefore when combining tetramisoles with macrocylic lactones, to stabilize the macrocyclic lactones at an alkali pH but at the same time to ensure that tetramisoles are also stable and prevented from crystallising out of solution in a low alkali environment.
m:\speci\120000\1 26-127\1261 OOcmpgrb.doc in N, The present invention provides a stable preparation containing a mixture of
O
tetramisole and macrocyclic lactone in an alkaline medium without the need for formation of an emulsion or micelle solution.
O In a first aspect the present invention provides a parasiticidal composition having a pH of at least 7, said composition comprising an effective amount of at least one tetramisole and at least one macrocyclic lactone; one or more polyols, and one or more organic acids.
The present inventor has surprisingly found that polyols and organic acids may be used to stabilise a parasitical preparation containing a mixture of actives including macrocyclic lactones and tetramisoles.
In another aspect therefore, the invention provides the use of a liquid composition having a pH of at least 7, which composition comprises one or more polyols and one or more organic acids, to stabilise at least one tetramisole and at least one macrocyclic lactone and to facilitate the administration of a parasiticidally effective amount of said at least one tetramisole and at least one macrocyclic lactone to an animal.
In yet another aspect, the present invention provides a method for treating parasitic infections in an animal comprising administering to the animal a parasticidally effective amount of a composition having a pH of at least 7, said composition comprising at least one tetramisole, at least one macrocyclic lactone, one or more polyols and one or more organic acids.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
The composition of the present invention is suitable for oral and/or topical administration to an animal for example in the form of a drench, a pour-on or a sprayon. The composition may also be administered as an injection including subcutaneous and intramuscular injection.
The pH of the composition is at least 7, preferably in the range of from 7 to 12 and more preferably in the range of from 7 to 9.
One or more polyols are included in the composition and these may be selected from the group consisting of propylene glycol, glycerol, sorbitol, polyethylene glycol and mixtures thereof. Broadly, the polyols may be included in an amount of from 400 to 980 g/L. Preferably, they are used in an amount of from 800 to 980 g/L. In the case of sorbitol, it is usual to provide the sorbitol as a 70% w/v aqueous solution. In m:\speci\120000\1 26-127\126100cmpgrb.doc n 4 Saddition, in order for the polyethylene glycols to be liquid, there molecular weight will U generally be in the range of about 300-600. However, potentially solid polyethylene glycols could be used in combination with one or more suitable co-solvents.
COne or more organic acids are included in the composition and these may be selected from the group consisting of C 1
C
6 carboxylic acid, C 2
C
6 dicarboxylic acid and mixtures thereof. Suitable organic acids include but are not limited to, methanoic acid, ethanoic acid, lactic acid, propionic acid, caproic acid, ethandioic acid, hexanedioic acid and mixtures thereof. Preferred are lactic acid and ethanoic acid and most preferred is ethanoic acid. Broadly, the organic acids may be included in an 010 amount of 0.1 100 g/L. Preferably, they are used in an amount of from 0.2 50 g/L.
C Suitable tetramisoles include those suitable for veterinary use such as levamisole. The tetramisoles are included in an effective amount such as in an amount from 5 to 250 g/L, preferably from 10 to 50 g/L.
The macrocyclic lactones include those suitable for veterinary use and may be selected from the group consisting of ivermectin, avermectin, doramectin, milbemycin oxime, moxidectin and mixtures thereof. As used herein, the term "avermectin" refers to avermectin Bl, also known as abamectin, being a mixture containing avermectin Bla and avermectin Bib. The macrocyclic lactones are included in an effective amount such as in an amount from 0.1 to 10 g/L, preferably, from 0.5 to 2.0 g/L.
The composition of the present invention may include one or more other parasiticide actives such as those from the chemical classes of benzimidazoles, salicylanilides, pyrazino isoquinoline derivatives and organophosphates.
Benzimidazoles, salicylanilides and pyrazino isoquinoline derivatives may each be included in the composition in amounts of from 5 to 250 g/L, preferably 10 to 50 g/L.
Organophosphates may be included in amounts of from 20 to 400g/L, preferably 70 to 200 g/L.
Suitable benzimidazoles include, but are not limited to thiabendazole, cambendazole, parbendazole, mebendazole, fenbendazole, oxfendazole, oxibendazole, albendazole, albendazole sulfoxide, thiophanate, febantel, netobimin, and triclabendazole. Suitable salicylanilides include, but are not limited to brotianide, clioxanide, closantel, niclosamide, oxyclozanide and rafoxanide. Suitable pyrazino isoquinoline derivative include, but are not limited to praziquantel. Suitable organophosphates include, but are not limited to naphthalophos and cythioate.
Veterinarily acceptable excipients and adjuvants may be included in the composition such as solvents, stabilisers, pH adjusters, dyes, flavouring agents, preservatives and thickening agents. A person skilled in the art would be well aware of m:\speci\120000\126-127\126100cmpgrb.doc appropriate adjuvants suitable for oral and topical veterinary preparation. Suitable thickening agents include xanthan gum, colloidal silicon dioxide, cellulose gum, guar gum. Polyvinylpyrrolidone (PVP) may be used as a stabiliser. Preferred PVP's are those with a K value of 12 to 97 such as PVP-K15, PVP-K30 and Modes for carrying out the invention In order to better understand the nature of this invention, a number of examples will be described.
Ingredient Example 1 Example 2 Example 3 Function g/L g/L g/L Benzimidazoles 25 25 25 Active Albendazole Mebendazole Albendazole Salicylanilides 38 38 Active Closantel Oxyclozanide Macrocyclic lactones 1 1 1 Active Abamectin Ivermectin Abamectin Tetramisoles 34 34 34 Active Levamisole Levamisole Levamisole Pyrazino -18.8 Active isoquinoline Praziquantel derivates Organophosphate 120 Active Naphthalophos Polyols 800 900 q.s. to 1 L Solvent Propylene Glycol 10 Acetic Acid organic acids Benzyl alcohol Polyvinylpyrrolidone PEG 30 2 1:1 Acetic Acid Lactic Acid 5 10 PVP-K90 Propylene Glycol 5 Acetic Acid 20 PVP-K29 Stabiliser Co-solvent Stabiliser 5 30 PVP-K29 m:\speci\120000\126-127\1261 OOcmpgrb.doc Ingredient Sodium hydroxide Water Example 1 30 Example 2 911 3 Example 3 Function pH adjustment Diluent q.s. tolIL q.s. tolIL Table 1 Ingredient Availability Ingredient Available from Albendazole Pacific Resources International Pty Ltd
("PRI'
t -Mebendazole
PRI
Closantel PRI -Oxyclosanide
PRI
-Abamnectin
PRI
Ivermectin
PMI
Levamisole PRI -Praziguantel
PRI
-Napthalophos
PRI
-Propylene glycol
PRI
PEG 30 PMI Acetic acid Asia Pacific Specialty Ltd ("APS") Lactic acid -APS -Benzyl alcohol
APS
_PVP-K29, K90 Redox Chemicals Sodiumn hydroxide
APS
In examples 1, 2 and 3, tetramisoles and macrocyclic lactones were dissolved in the polyols. Other actives and excipients were then be added to the mixture. The final mixture was adjusted to pH 7.0 9.0 by using the organic acid followed by homogenisation until uniform.
m:\speci\1 20000\1 26-1 27\1 261O0cmpgrb.doc Table 2 Stability Evaluation of Example 1 Storage Time Abendazole Abamectin Levamisole Closantel g/L g/L g/L g/L Temperature Temperature Temperature Temperature 0 C 30 0 C 30 0 C 30 0
C
Initial 26.2 0.95 33.7 40.9 1 month 25.8 0.95 34.0 40.6 The stability of Example 1 was evaluated by storing samples for various times at 0 C. The results of the stability trial is set out in Table 2 from which it can be seem that the samples were stable for the time tested. The result for levamisole is within allowable analytical error.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
m:\speci\120000\126-127\1261 OOcmpgrb.doc
Claims (3)
- 2. The composition according to claim 1 wherein the at least one polyol is selected C from the group consisting of propylene glycol, glycerol, sorbitol and polyethylene glycol, preferably propylene glycol and mixtures thereof; the at least one organic acid is selected from the group consisting of C 1 C 6 carboxylic acid and C 2 C 6 dicarboxylic acid, preferably methanoic acid, ethanoic acid, lactic acid, propionic acid, caproic acid, ethandioic acid, hexanedioic acid and mixtures thereof.
- 3. The composition according to claim 1 or claim 2 wherein the at least one polyol is in an amount of from 800 to 980 g/L and the at least one organic acid is in an amount of 0.2 50 g/L.
- 4. The composition according to any one of claims 1 to 3 wherein the at least one tetramisole is in an amount of from 5 to 250 g/L, preferably from 10 to 50 g/L; and the at least one macrocyclic lactone is in an amount of from 0.1 to 10 g/L, preferably from to 2.0 g/L. The use of a liquid composition having a pH of at least 7, which composition comprises one or more polyols and one or more organic acids, to stabilise at least one tetramisole and at least one macrocyclic lactone and to facilitate the administration of a parasiticidally effective amount of said at least one tetramisole and at least one macrocyclic lactone to an animal. Dated this twentieth day of December 2005 Jurox Pty Ltd Patent Attorneys for the Applicant: F B RICE CO m:\speci\120000\1 26-127\1261 OOcmpgrb.doc
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005101039A AU2005101039B4 (en) | 2005-12-20 | 2005-12-20 | Stable Parasiticide Composition |
| NZ54674706A NZ546747A (en) | 2005-12-20 | 2006-04-26 | Stable parasiticide composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005101039A AU2005101039B4 (en) | 2005-12-20 | 2005-12-20 | Stable Parasiticide Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005101039A4 AU2005101039A4 (en) | 2006-02-02 |
| AU2005101039B4 true AU2005101039B4 (en) | 2006-03-30 |
Family
ID=35940874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005101039A Expired AU2005101039B4 (en) | 2005-12-20 | 2005-12-20 | Stable Parasiticide Composition |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2005101039B4 (en) |
| NZ (1) | NZ546747A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ594610A (en) | 2011-08-16 | 2013-03-28 | Virbac New Zealand Ltd | Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants |
-
2005
- 2005-12-20 AU AU2005101039A patent/AU2005101039B4/en not_active Expired
-
2006
- 2006-04-26 NZ NZ54674706A patent/NZ546747A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ546747A (en) | 2006-10-27 |
| AU2005101039A4 (en) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10864195B2 (en) | Topical localized isoxazoline formulation | |
| ES2620413T3 (en) | Topical anthelmintic veterinary formulations | |
| RU2602189C2 (en) | Topical localized isoxazoline formulation comprising glycofurol | |
| EP2833867B1 (en) | Solid oral pharmaceutical compositions for isoxazoline compounds | |
| JP7269927B2 (en) | Injectable isoxazoline pharmaceutical compositions and their use against parasitic infestations | |
| JP7558197B2 (en) | Injectable pharmaceutical compositions and uses thereof | |
| JP7703611B2 (en) | Injectable pharmaceutical compositions and uses thereof | |
| US7687471B2 (en) | Benzimidazole non-aqueous compositions | |
| EP2983712B1 (en) | Composition of macrocyclic lactones, levamisole, an amino sugar and an additional antiparasitic agent | |
| AU2005101039A4 (en) | Stable Parasiticide Composition | |
| CN1822880B (en) | Parasiticidal composition | |
| JP2002506819A (en) | Sulfur pentafluorophenyl pyrazole for controlling ectoparasite infestation | |
| AU2007100254A4 (en) | Improved parasiticide paste | |
| WO2025191150A2 (en) | Stable isoxazoline formulation for topical application to the skin | |
| AU2013204176B2 (en) | Stable veterinary combination formulations of macrocyclic lactones and imidazothiazoles | |
| AU2007221747A1 (en) | Medicament | |
| HK40037157B (en) | Injectable isoxazoline pharmaceutical compositions and their use against parasite infestation | |
| HK40037157A (en) | Injectable isoxazoline pharmaceutical compositions and their use against parasite infestation | |
| BR102013017846A2 (en) | Ultraconcentrated active nanoformulations and submicroformulations with antispasmodic dendrimers and / or aines (non-hormonal anti-inflammatory drugs) and / or antihistamines or aies (anti-inflammatory hormones) and / or cyclosporins for the purpose of redeeming symptoms of inflammation, colic, itching and pain in cattle, swine, goats, sheep, canines and felines or benzoyl urea and / or acyl urea and / or avermectins alone or combined with vermifuge and / or insecticides for the control and prevention of endo and ectoparasites in cattle, pigs, goats, sheep, canines, felines and birds | |
| HK1116007A (en) | Spot-on formulations for combating parasites | |
| HK1116007B (en) | Spot-on formulations for combating parasites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |